

EPISODES OF CARE

Results of Episodes of Care Program

CY 2015	CY 2016	CY 2017	CY 2018	CY 2019
Savings*: \$10.8 million Providers and hospitals reduced costs while maintaining quality of care Gain sharing payments to providers exceeded risk sharing payments by \$280,000	Estimated Savings*: \$14.5 million • Quality metrics improved for perinatal, total joint replacement, and COPD, and were mostly maintained for the remaining episodes • Gain sharing payments to providers exceeded risk sharing payments by \$395,000	Estimated Savings*: \$28.6 million • Quality metrics improved or maintained for most episodes • Gain sharing payments to providers exceeded risk sharing payments by \$206,900	Estimated Savings*: \$38.3 million • Quality metrics improved or maintained for most episodes • Gain sharing payments to providers exceeded risk sharing payments by \$686,000	Estimated Savings*: \$45.2 million • Quality metrics improved or maintained for most episodes • Gain sharing payments totaled \$1.9 million • Due to COVID-19, all risk-sharing payments have been waived for the 2019 performance period
ncludes the 3 episodes in performance in CY 2015	Includes the 8 episodes in performance in CY 2016	Includes the 19 episodes in performance in CY 2017	Includes the 27 episodes in performance in CY 2018	Includes the 45 episodes in performance in CY 2019



SAVINGS RESULTS

2019 Episodes Savings

Episodes estimated savings for 2019 is approximately **\$45.2 million** due to episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

Episode Type	Projected	Actual	Estimated Savings per Episode	Percent Savings per Episode	Number of Valid Episodes	Total Estimated Savings
Total	-	-	-	-	740,401	\$45,158,436
Perinatal	\$7,759	\$7,247	\$512	6.6%	20,457	\$10,473,905
Asthma Acute Exacerbation	\$1,365	\$841	\$525	38.4%	10,404	\$5,457,829
Total Joint Replacement	\$14,047	\$13,437	\$610	4.3%	269	\$164,073
Cholecystectomy	\$5,084	\$4,677	\$407	8.0%	1,392	\$567,197
Colonoscopy	\$1,215	\$932	\$283	23.3%	2,292	\$648,296
COPD	\$2,611	\$2,042	\$569	21.8%	3,461	\$1,968,560
Acute PCI	\$10,245	\$11,724	-\$1,479	-14.4%	217	-\$320,948
Non-acute PCI	\$7,568	\$8,237	-\$669	-8.8%	23	-\$15,386
GIH	\$3,894	\$4,081	-\$187	-4.8%	1,011	-\$188,569
EGD	\$1,323	\$1,110	\$212	16.1%	6,695	\$1,422,227
Respiratory Infection	\$132	\$109	\$23	17.5%	359,282	\$8,304,576
Pneumonia	\$1,337	\$1,305	\$32	2.4%	2,483	\$78,986
UTI-Outpatient	\$165	\$136	\$28	17.3%	31,520	\$896,832
UTI-Inpatient	\$4,459	\$3,632	\$828	18.6%	973	\$805,299
CHF acute exacerbation	\$6,277	\$5,926	\$351	5.6%	2,049	\$719,036
ODD	\$1,447	\$950	\$497	34.3%	1,734	\$861,408
CABG	\$31,502	\$30,673	\$829	2.6%	88	\$72,917
Valve Repair and Replacement	\$77,070	\$39,252	\$37,817	49.1%	6	\$226,904
Bariatric Surgery	\$8,559	\$9,119	-\$560	-6.5%	602	-\$337,230
ADHD	\$1,366	\$1,059	\$307	22.5%	20,925	\$6,432,977
Breast Biopsy	\$1,836	\$1,564	\$273	14.8%	656	\$178,821
Otitis Media	\$167	\$150	\$17	10.1%	116,374	\$1,968,796
Tonsillectomy	\$2,802	\$2,503	\$299	10.7%	5,825	\$1,740,388
SSTI	\$232	\$246	-\$14	-6.1%	39,440	-\$559,090
HIV	\$1,044	\$847	\$197	18.9%	1,530	\$301,377

2019 Episodes Savings

Episodes estimated savings for 2019 is approximately **\$45.2 million** due to episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

			Estimated			Total
			Savings per	Percent Savings	Number of Valid	Estimated
Episode Type	Projected	Actual	Episode	per Episode	Episodes	Savings
Total	-	-	-	-	740,401	\$45,158,436
Pancreatitis	\$6,393	\$5,978	\$415	6.5%	437	\$181,429
Acute Diabetes Exacerbation	\$5,792	\$5,582	\$210	3.6%	717	\$150,333
Spinal Fusion	\$21,794	\$21,863	-\$69	-0.3%	371	-\$25 <i>,</i> 760
Spinal Decompression without						
Fusion	\$5,757	\$5,869	-\$112	-1.9%	119	-\$13,332
Femur/Pelvic Fracture	\$16,563	\$16,252	\$312	1.9%	88	\$27,428
Knee Arthroscopy	\$3,264	\$3,267	-\$3	-0.1%	847	-\$2,915
Non-operative Ankle Injury	\$327	\$335	-\$8	-2.5%	14,749	-\$121,668
Non-operative Wrist Injury	\$372	\$360	\$12	3.1%	7,900	\$92,560
Non-operative Shoulder Injury	\$349	\$355	-\$6	-1.6%	6,517	-\$36,013
Non-operative Knee Injury	\$409	\$409	\$0	0.1%	6,683	\$3,243
Back/Neck Pain	\$402	\$379	\$23	5.8%	46,777	\$1,092,518
Acute Seizure	\$1,503	\$1,460	\$43	2.9%	5,783	\$249,372
Syncope	\$681	\$622	\$58	8.6%	6,100	\$355,031
Bronchiolitis	\$665	\$651	\$14	2.1%	4,550	\$62,778
Pediatric Pneumonia	\$930	\$832	\$98	10.5%	3,170	\$309,595
Colposcopy	\$382	\$391	-\$10	-2.6%	2,815	-\$27,647
Hysterectomy	\$5,246	\$5,235	\$11	0.2%	712	\$7,846
Gastrointestinal Obstruction	\$9,143	\$7,831	\$1,312	14.3%	304	\$398,723
Appendectomy	\$5,273	\$5,151	\$122	2.3%	851	\$103,513
Hernia Repair	\$4,445	\$4,044	\$401	9.0%	1,203	\$482,218



QUALITY RESULTS

Wave 1 Episodes*	CY 2014	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	Target Performance
Perinatal							
1. HIV Screening (≥ 85%)	90.2%	88.3%	87.7%	89.1%	92.8%	94.6%	Higher is better
2. Group B Streptococcus							
Screening (≥ 85%)	87.8%	85.9%	94.0%	95.5%	95.2%	96.7%	Higher is better
3. C-Section Rate (≤ 38%)	30.5%	31.6%	30.6%	31.2%	30.8%	29.9%	Lower is better
Asthma Acute Exacerbation	1						
1. Follow-up Visit with							
Physician (≥ 30%)	N/A**	N/A**	29.6%	30.3%	32.4%	30.8%	Higher is better
2. Patient on Appropriate							
Medication (≥ 60%)	N/A**	N/A**	60.3%	65.4%	69.5%	66.8%	Higher is better

Note: There are no quality metrics tied to gain sharing for the total joint replacement episode



^{*}Valid episodes in 2019 performance period across all three MCOs

^{**}There was a coding change to these quality metrics so there is no direct comparison

						Target
Wave 2 Episodes*	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	Performance
Cholecystectomy						
1. Hospitalization in Post-Trigger						
Window (≤ 10%)	0.8%	1.0%	0.9%	0.3%	0.2%	Lower is better
COPD						
1. Follow-up Care Within Post-						
Trigger Window (≥ 45%)	45.1%	46.7%	47.4%	46.7%	48.1%	Higher is better
Acute PCI						
1. Hospitalization in Post-Trigger						
Window (≤ 10%)	1.0%	0.7%	0.7%	1.1%	0.9%	Lower is better
Non-acute PCI						
1. Hospitalization in Post-Trigger						
Window (≤ 10%)	0.0%	1.6%	0.0%	0.0%	0.0%	Lower is better

Note: There are no quality metrics tied to gain sharing for the colonoscopy episode

*Valid episodes in 2019 performance period across all three MCOs



Wave 3 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	Target Performance
GI Hemorrhage					
1. Follow-up Care Within Post-Trigger					
Window (≥ 45%)	49.0%	51.9%	50.1%	50.0%	Higher is better
Pneumonia					
1. Follow-up Care Within Post-Trigger					
Window (≥ 30%)	N/A**	N/A**	30.4%	30.4%	Higher is better
UTI-Inpatient					
1. Follow-up Care Within Post-Trigger					
Window (≥ 40%)	46.0%	43.5%	42.4%	41.1%	Higher is better
UTI-Outpatient					
1. Admission Within the Trigger					
Window for ED Triggered Episodes (≤					
5%)***	5.6%	6.1%	7.0%	6.3%	Lower is better
2. Admission Within the Trigger					
Window for Non-ED Triggered					
Episodes (≤ 5%)***	0.8%	1.0%	1.0%	1.0%	Lower is better

Note: There are no quality metrics tied to gain sharing for the EGD and respiratory infection episodes



^{*}Valid episodes in 2019 performance period across all three MCOs

^{**}There was a coding change to these quality metrics so there is no direct comparison

^{***}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.

Wave 4 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	Target Performance
Bariatric Surgery	C1 2010	G1 2011	C1 2010	G1 2019	renormance
Follow-up Care Within Post-Trigger Window					
(≥ 30%)	35.6%	37.4%	43.3%	43.0%	Higher is better
CHF Acute Exacerbation					
1. Follow-up Care Within Post-Trigger Window					
(≥ 60%)	56.2%	57.2%	57.0%	56.0%	Higher is better
ODD					
1. Minimum Care Requirement (≥ 30%)	26.7%	35.8%	31.9%	30.7%	Higher is better
CABG					
Follow-up Care Within Post-Trigger Window					
(≥ 90%)	71.4%	70.0%	78.5%	81.6%	Higher is better
Valve Repair and Replacement					
Follow-up Care Within Post-Trigger Window					
(≥ 90%)	78.5%	77.7%	76.7%	100.0%	Higher is better
ADHD					
1. Minimum Care Requirement (≥ 70%)	N/A**	78.5%	78.8%	77.6%	Higher is better
2. Long-acting Stimulants for Members Aged 6					
to 11 Years (≥ 80%)***	N/A**	83.1%	82.9%	83.6%	Higher is better
3. Long-acting Stimulants for Members Aged 12					
to 20 Years (≥ 80%)***	N/A**	83.0%	83.1%	83.9%	Higher is better
4. Utilization of Therapy for Members Aged 4	.				
and 5 Years (1 visit)***	N/A**	1.42	1.71	1.60	Higher is better

^{*}Valid episodes in 2019 performance period across all three MCOs

^{***} This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes



^{**}The preview period for the ADHD episode was 2017. The initial performance period for the ADHD episode was 2018

Wave 5 Episodes*	CY 2017	CY 2018	CY 2019	Target Performance
Breast Biopsy	<u> </u>	0. 20.0		
1. Appropriate Diagnostic Workup Rate (≥ 90%)	82.8%	80.8%	85.1%	Higher is better
2. Core Needle Biopsy Rate (≥ 85%)**	77.5%	82.2%	92.0%	Higher is better
Tonsillectomy				
1. Bleeding Up to Two Days Following the				
Procedure (≤ 10%)	0.7%	0.5%	0.7%	Lower is better
Otitis Media				
1. Otitis Media with Effusion (OME) Episodes				
without Antibiotics Filled (≥ 25%)**	27.7%	26.2%	31.6%	Higher is better
2. Non-OME Episodes with Amoxicillin (≥ 60%)**	64.3%	66.9%	65.1%	Higher is better



^{*}Valid episodes in 2019 performance period across all three MCOs

^{**} This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

Wave 6 Episodes*	CY 2017	CY 2018	CY 2019	Target Performance
Skin and Soft Tissue Infection				
1. Bacterial Cultures when Incision and Drainage				
Performed (≥ 50%)**	42.4%	42.5%	40.7%	Higher is better
2. SSTI Episodes with a First Line Antibiotic (≥				
85%)**	97.7%	97.8%	98.0%	Higher is better
HIV				
1. Periodic anti-retroviral therapy (ART) refill (≥ 85%)	71.6%	73.1%	73.8%	Higher is better
Acute Diabetes Exacerbation				
1. Follow-up care in the first 14 days of the post-				
trigger window (≥ 30%)	25.4%	30.6%	30.3%	Higher is better
Pancreatitis				
1. Follow-up care in the first 14 days of the post-				
trigger window (≥ 35%)	31.9%	35.8%	30.7%	Higher is better



^{*}Valid episodes in 2018 performance period across all three MCOs

^{**}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

Wave 7 Episodes*	CY 2018	CY 2019	Target Performance
Spinal Fusion			
1. Difference in Average MED/Day (≤ 8.0)	0.04	4.26**	Lower is better
Spinal Decompression without Fusion			
1. Difference in Average MED/Day (≤ 0.0)	1.38	5.71**	Lower is better
Femur/Pelvic Fracture			
1. Related follow-up care (≥ 30%)	6.8%	9.6%	Higher is better
2. Difference in Average MED/Day (≤ 8.0)	2.00	0.97	Lower is better
Knee Arthroscopy			
1. Difference in Average MED/Day (≤ 0.0)	-0.96	0.66	Lower is better
Non-operative Ankle Injury			
1. Difference in Average MED/Day (≤ 0.0)	0.02	0.38	Lower is better
Non-operative Wrist Injury			
1. Difference in Average MED/Day (≤ 0.0)	0.11	0.47	Lower is better
Non-operative Shoulder Injury			
1. Difference in Average MED/Day (≤ 0.0)	0.45	0.78	Lower is better
Non-operative Knee Injury			
1. Difference in Average MED/Day (≤ 0.0)	0.73	0.05	Lower is better
Back/Neck Pain			
1. Difference in Average MED/Day (≤ 0.0)	1.98	2.28	Lower is better

^{*}Valid episodes in 2019 performance period across all three MCOs

^{**}This quality metric is based on a formula related to opioid prescriptions. The increase for these metrics was driven by a few episode outliers that are being investigated and addressed by the Managed Care Organizations and aligned with TennCare's overall opioid strategy. For more information on TennCare's Opioid Strategy, please visit the following website - https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html



Move 9 Epicodos*	CY 2018	CY 2019	Target Performance
Wave 8 Episodes* Acute Seizure	C1 2016	C1 2019	Performance
1. Brain MRI Utilization in Focal Epilepsy (≥ 10%)**	18.0%	18.7%	Llighar is battar
2. Prolonged EEG Monitoring Utilization in Newly	10.0 /6	10.7 /0	Higher is better
Diagnosed Seizure (≥ 10%)**	7.4%	5.7%	Higher is better
Syncope			J
1. Carotid Ultrasound Imaging in Adults (≤ 10%)**	5.8%	4.0%	Lower is better
Bronchiolitis			
1. Related Admission during the Post-Trigger Window (≤			
10%)	1.1%	1.1%	Lower is better
2. Utilization of Bronchodilators (≤ 30%)	14.4%	16.9%	Lower is better
3. Utilization of Steroids (≤ 50%)	22.0%	22.4%	Lower is better
Pediatric Pneumonia			
 Related Admission during the Post-Trigger Window (≤ 			
10%)	1.3%	1.2%	Lower is better
2. Utilization of Macrolides in Patients Under 6 Years Old			
<u>(</u> ≤ 30%)**	19.7%	20.7%	Lower is better
3. Utilization of Narrow Spectrum Antibiotics (≥ 50%)	52.0%	57.6%	Higher is better



^{*}Valid episodes in 2019 performance period across all three MCOs

^{**}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes

Wave 8 Episodes*	CY 2018	CY 2019	Target Performance
Colposcopy			
1. LEEP Utilization Under 26 Years Old With No Evidence			
of High-Grade Dysplasia (≤ 10%)**	4.2%	4.2%	Lower is better
2. LEEP Utilization with Low-grade Dysplasia (≤ 10%)**	9.5%	7.0%	Lower is better
Hysterectomy			
1. Alternative Treatments (≥ 20%)	31.0%	34.2%	Higher is better
2. Related Follow-up Care (≥ 10%)	19.2%	20.1%	Higher is better
GI Obstruction			
1. Related Follow-up Care (≥ 20%)	33.0%	32.6%	Higher is better
2. Difference in Average MED/Day (≤ 0.0)	4.13	3.31	Lower is better
Appendectomy			
1. Abdominopelvic CT Scans in Children (≤ 50%)**	42.4%	36.9%	Lower is better
1. Difference in Average MED/Day (≤ 0.0)	-0.21	-0.09	Lower is better
Hernia Repair			
1. Difference in Average MED/Day (≤ 0.0)	0.12	0.63	Lower is better



^{*}Valid episodes in 2019 performance period across all three MCOs

^{**}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes